| Pharmaceutical Information |
| Drug Name |
Ciclopirox |
| Drug ID |
BADD_D00461 |
| Description |
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor. |
| Indications and Usage |
Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum. |
| Marketing Status |
approved; investigational |
| ATC Code |
D01AE14; G01AX12 |
| DrugBank ID |
DB01188
|
| KEGG ID |
D03488
|
| MeSH ID |
D000077768
|
| PubChem ID |
2749
|
| TTD Drug ID |
D07GRH
|
| NDC Product Code |
50090-6562; 63629-8620; 63629-8621; 68788-6797; 0574-2061; 0591-2159; 49706-1440; 99207-010; 51014-7851; 42192-714; 43538-500; 45802-141; 63629-8623; 42192-715; 50383-419; 51672-1351; 63629-8622; 68462-455; 64552-8110; 0713-0317; 17337-0506; 71052-661; 45802-401; 51672-1323; 51672-5302 |
| UNII |
19W019ZDRJ
|
| Synonyms |
Ciclopirox | Cyclopirox | HOE 296 | HOE-296 | HOE296 | Ciclopirox Olamine | Cyclopyroxolamine | 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt | Ciclopiroxolamine | Loprox | Batrafen | Penlac | Dafnegin-CSC | Dafnegin CSC |
|
| Chemical Information |
| Molecular Formula |
C12H17NO2 |
| CAS Registry Number |
29342-05-0 |
| SMILES |
CC1=CC(=O)N(C(=C1)C2CCCCC2)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Application site hypersensitivity | 08.02.01.013; 10.01.03.009; 12.07.01.014 | - | - | - |
|
|
|
